This company has shut down. Ambys Medicines is no longer operating — its last tracked round was a Series A in 2021.
Explore the Startup GraveyardAmbys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies.
Ambys Medicines has raised $47.0M in total funding. The most recent round was Series A. The last funding was announced in December 2021.
Ambys Medicines's investors include Schroders Capital, Third Rock Ventures, Takeda, Smilegate Investment, Alexandria Venture Investments.
Ambys Medicines is headquartered in South San Francisco, United States.
Ambys Medicines is a biotechnology company focused on discovering and developing regenerative and restorative therapies.
Ambys Medicines is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ambys Medicines — Funding & Investors." VCBacked, December 21, 2021, https://www.vcbacked.co/company/ambys-medicines. Accessed August 15, 2026.
VCBacked. (2021). Ambys Medicines — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/ambys-medicines
{{cite web |title=Ambys Medicines — Funding & Investors |url=https://www.vcbacked.co/company/ambys-medicines |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated